**Solid Tumors: Dose Escalation Only (Disease-Specific Expansion)**

- **Advanced solid tumors with positive HER2 expression**
  - Expansion: advanced/metastatic gastroesophageal cancer or colorectal cancer with positive HER2 expression
  - **10358**: Phase 1/IB Study of DS8201a in Combination with ATR Inhibition (AZD6738) in Advanced Solid Tumors with HER2 Expression (DASH Trial)

- **Solid tumors with PTEN or PIK3CB mutations**
  - Expansion: breast, prostate, other solid tumors
  - **10131**: Phase I Study of AZD8186 in Combination with Docetaxel in Patients with PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel

- **Solid tumors, no specific mutations**
  - Expansion: at least one pancreatic cancer cohort and possibly others
  - **10244**: Phase I Study of GSK525762 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas
  - **10070**: Phase 1/2 Study of Navitoclax Plus Vistusertib in Patients with Relapsed Small Cell Lung Cancer (SCLC) and Other Solid Tumors
  - **10276**: A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies (Limited: Phase 1; ETCTN-wide: Phase 2)

- **Solid tumors in patients with known HIV infection**
  - Expansion: metastatic/ recurrent Kaposi sarcoma
  - **10387**: Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients with HIV Infection

**ETCTN Trials by Disease/Treatment Area:** Solid Tumors - Dose Escalation Only (Disease-Specific Expansion)

**NOTE:** * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: July 13, 2020